Table 1 Baseline characteristics
Variable | Value |
|---|---|
Age, years, median (range) | 46 (18−69) |
Sex, female, n (%) | 8 (80 %) |
Race, n (%) | |
Caucasian | 5 (50 %) |
African American | 3 (30 %) |
Disease duration, median (range) | 0.7 (0.5−1.7) |
ANA-positive, n (%) | 9 (90 %) |
Anti-Scl 70-positive, n (%) | 3 (30 %) |
RNA polymerase III-positive, n (%) | 5 (50 %) |
MRSS at baseline, mean ± SD | 30.1 ± 8.2 |
Mean change in MRSS in 1 month prior to baseline, mean ± SD | +2.9 ± 3.4 |
Tendon friction rubs, n (%) | 4 (40 %) |
Previous treatment, n (%) | |
Methotrexate | 2 (20 %) |
No immunosuppression | 8 (80 %) |